Drug Trial Radar · NCT03856827
A Study of IW-6463 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Feb 6, 2019
Primary completion
Oct 22, 2019
Study completion Oct 22, 2019
Sponsor
- Lead sponsor
- Tisento TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Stage 1: To assess the safety and tolerability of single-ascending-dose levels of IW-6463 tablets when administered orally to healthy subjects Stage 2: To assess the safety and tolerability of multiple-ascending-dose levels of IW-6463 tablets administered orally to healthy subjects Stage 3: To assess the safety and tolerability of a single dose of IW-6463 when administered to health subjects in fed vs fasted states and explore the effects of food on IW-6463 pharmacokinetics (PK)
Conditions
- Other
Interventions
IW-6463Drug
IW-6463 Tablet
Matching PlaceboDrug
Matching Placebo Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- After single ascending doses, number of subjects with treatment-emergent adverse events (TEAEs) in the IW-6463 dose-level cohorts vs the (pooled) placebo group.Time frame: Up to 9 days
- After multiple ascending doses, number of subjects with TEAEs in the IW-6463 dose-level cohorts vs the (pooled) placebo group.Time frame: Up to 32 days
- After a single dose, number of subjects with TEAEs in the fed vs fasted dosing periodTime frame: Up to 28 days
- Plasma concentration of IW-6463 after single-dose administration under fed vs fasted conditionsTime frame: Up to 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Human Drug Research
Leiden, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.